Intech Investment Management LLC Buys Shares of 12,285 Nevro Corp. (NYSE:NVRO)

Intech Investment Management LLC purchased a new stake in Nevro Corp. (NYSE:NVRO) during the 3rd quarter, Holdings Channel reports. The firm purchased 12,285 shares of the medical equipment provider’s stock, valued at approximately $69,000.

A number of other hedge funds also recently made changes to their positions in NVRO. Nisa Investment Advisors LLC lifted its holdings in Nevro by 1,788.8% in the second quarter. Nisa Investment Advisors LLC now owns 6,932 shares of the medical equipment provider’s stock worth $58,000 after purchasing an additional 6,565 shares during the period. SG Americas Securities LLC bought a new stake in shares of Nevro during the 3rd quarter worth about $71,000. Canada Pension Plan Investment Board raised its position in shares of Nevro by 345.8% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,700 shares of the medical equipment provider’s stock worth $90,000 after buying an additional 8,300 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Nevro by 84.6% in the 2nd quarter. XTX Topco Ltd now owns 24,711 shares of the medical equipment provider’s stock worth $208,000 after acquiring an additional 11,323 shares during the period. Finally, Hsbc Holdings PLC boosted its holdings in shares of Nevro by 21.4% in the second quarter. Hsbc Holdings PLC now owns 55,604 shares of the medical equipment provider’s stock valued at $459,000 after acquiring an additional 9,793 shares in the last quarter. Institutional investors own 95.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on NVRO shares. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. Robert W. Baird boosted their price objective on Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Wells Fargo & Company began coverage on Nevro in a report on Tuesday, December 3rd. They issued an “equal weight” rating and a $5.00 price objective for the company. JMP Securities reaffirmed a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Finally, Canaccord Genuity Group cut their price target on shares of Nevro from $8.00 to $7.00 and set a “hold” rating for the company in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.55.

Nevro Trading Up 2.9 %

Shares of NVRO opened at $4.19 on Monday. Nevro Corp. has a 1-year low of $3.95 and a 1-year high of $22.64. The business’s 50-day moving average price is $4.84 and its 200 day moving average price is $6.64. The stock has a market capitalization of $157.01 million, a P/E ratio of -2.22 and a beta of 0.84. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The business had revenue of $96.60 million for the quarter, compared to analyst estimates of $93.09 million. During the same quarter in the previous year, the business earned ($0.65) earnings per share. The firm’s revenue was down 7.0% compared to the same quarter last year. Analysts expect that Nevro Corp. will post -2.43 earnings per share for the current year.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.